ORIC: Oric Pharmaceuticals, Inc.
Performance
ORIC -25.26%
Watchlist
Select an item
Summary
ORIC at a glance
ORIC returned -25.26% over the past year and -10.68% a year over five years. Its worst drop in that year was -46.15%, smaller than 28% of stocks on Redstone, and its Sharpe ratio of 0.13 beats 32% of stocks on Redstone. It pays no dividends.
Current Drawdown
-37.00%
Rolling Volatility
131.27%
Actions
Metrics
Risk Indicators
Alpha-1.42%
Beta1.29x
Sharpe0.13
Sortino0.17
Omega1.03
Calmar-0.55
Martin0.46
Profile
About ORIC
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $957M
- Listed
- Apr 2020
- Employees
- 111
- Headquarters
- South San Francisco, CA
- Website
- oricpharma.com
Comparisons